trustworthy resource allocation in health: should the assessment of severity have a pandemic-premium?*

Lars Sandman*, Department of Health, Medicine and Caring Sciences; National Centre for Priorities in Health, Linköping University, Sweden

10.1136/bmjgh-2022-ISPH.61

The assessment of severity plays an essential role to conceptualize ideals about equity in several distributive theories and in mid-level operational principles in a number of healthcare jurisdictions, like Sweden, Norway and The Netherlands. Exactly how severity should be assessed is a matter of dispute, and it has been observed that several central issues concerning underlying rationales and operationalization are unresolved. One aspect, raised by the ongoing pandemic, but largely unanalyzed is how severity of a pandemic, like covid-19 should be assessed. Within the ongoing Norwegian project SEVPRI, Horn et al made an interesting analysis of the severity of covid-19, raising several issues that do not seem to be fully covered by the Norwegian perspective on severity – and I would say generally so. One such issue is the indirect effect a pandemic has even for patients suffering mild disease, in terms of potential spread of disease to patients that will suffer individually severe conditions.

In this talk I will explore whether the assessment of severity should take into account indirect effects in a pandemic and give a ‘pandemic-premium’ even to a mild condition, given the risk of spread and hence potentially severe consequences for other people. By comparing patient-populations where we in both cases effectively can avoid development of severe disease, in one case by treating people with mild disease and in one by treating people with severe disease, I will argue that we have a prima facie reason to either include a pandemic-premium to severity or add a further pandemic factor to consider. I will further explore how such a pandemic-premium should (and should not) be interpreted and explore some pros and cons of such a premium.
Background Inequalities in the health and non-health benefits of public health interventions are a key challenge on the path to universal health coverage, particularly in LMICs. The design of HBP creates an opportunity in selecting interventions through established criteria. A quantitative analytic method was employed for integrating the distributional health and financial protection impact during the prioritization of interventions.

Methods Data on average health benefits, costs, disease prevalence, and population size were extracted from the GBD and latest Ethiopian essential health service package (EHSP) database, survey, and published sources. Benefits were distributed across quintiles using a combined adjusted risk of disease prevalence and coverage, with the latter used to distribute total costs. For each intervention (30 in total), a 95% target coverage (applied to current coverage vs. to the gap in coverage across quintile) was analyzed. Inequality and social welfare indices, and financial protection metrics were estimated.

Results Twenty-four interventions were found to improve population health and reduce health inequality, 4 interventions to reduce population health and increase health inequality, and 2 interventions to improve population health and increase health inequality. In the case of the latter two, social welfare analysis using inequality aversion parameters (v=10) revealed that the health benefit outweighs the negative impact of health inequality.

Conclusion We found that improving access to the EHSP by reaching the uncovered population groups across each income group improves health equity; however, adding incremental coverage to existing coverage amplifies the existing health inequality more.

GRAIL has created a liquid biopsy [blood] test called ‘Galleri’ to screen for fifty different very early cancers. Widespread use of the test could save 100,000 lives per year in the US from a cancer death at a cost of $950. Grail recommends annual screening for everyone over age fifty, plus screening for anyone at elevated risk for cancer related to genetic, environmental, or behavioral factors. That represents 100 million individuals in the US at a cost of $95 billion annually. I argue that such an expenditure should be a low priority item, not warranted for both reasons of justice and financial prudence. The cost per life saved would be $950,000. No American insurance company or European government would likely see that as ‘high value’ care, given that 99% of the tests each year would be negative.

This is a ‘wicked’ challenge because every proposed allocation would create a different mix of injustices. If these costs were simply added to the cancer budget, we risk the injustices of ‘onco-exceptionalism.’ If these costs were subtracted from the US cancer budget of $211 billion, most metastatic cancer care (targeted therapies) would have to be foregone. If family history alone determined elevated cancer risk, younger individuals at elevated risk for cancer related to complex, polygenic risk factors would be denied this screening at social expense (and risk premature death). Whole genome sequencing could identify those individuals at a one-time cost of $500 billion, still requiring identifying a risk cutoff. Imagine the complexity of identifying environmental carcinogenic risk factors significant enough to justify the Galleri test. Imagine the publicly perceived injustice of paying for Galleri for smokers and sun-worshippers. I argue that a process of rational democratic deliberation is needed to achieve ‘rough justice’ regarding the screening use of liquid biopsies.

WICKED’ PRIORITY-SETTING CHALLENGES: LIQUID BIOSPIES FOR CANCER SCREENING

Leonard M Fleck*. Center for Bioethics and Social Ustice; Michigan State University; USA

GRAIL has created a liquid biopsy [blood] test called ‘Galleri’ to screen for fifty different very early cancers. Widespread use of the test could save 100,000 lives per year in the US from a cancer death at a cost of $950. Grail recommends annual screening for everyone over age fifty, plus screening for anyone at elevated risk for cancer related to genetic, environmental, or behavioral factors. That represents 100 million individuals in the US at a cost of $95 billion annually. I argue that such an expenditure should be a low priority item, not warranted for both reasons of justice and financial prudence. The cost per life saved would be $950,000. No American insurance company or European government would likely see that as ‘high value’ care, given that 99% of the tests each year would be negative.

This is a ‘wicked’ challenge because every proposed allocation would create a different mix of injustices. If these costs were simply added to the cancer budget, we risk the injustices of ‘onco-exceptionalism.’ If these costs were subtracted from the US cancer budget of $211 billion, most metastatic cancer care (targeted therapies) would have to be foregone. If family history alone determined elevated cancer risk, younger individuals at elevated risk for cancer related to complex, polygenic risk factors would be denied this screening at social expense (and risk premature death). Whole genome sequencing could identify those individuals at a one-time cost of $500 billion, still requiring identifying a risk cutoff. Imagine the complexity of identifying environmental carcinogenic risk factors significant enough to justify the Galleri test. Imagine the publicly perceived injustice of paying for Galleri for smokers and sun-worshippers. I argue that a process of rational democratic deliberation is needed to achieve ‘rough justice’ regarding the screening use of liquid biopsies.

Objective As more new- and high-cost treatments become available, there will be a greater need to decide whether the healthcare should withdraw and withhold these treatments from patients or not. When rationing health care, a commonly held view among ethicists is that there is no ethical difference between withdrawing or withholding medical treatments. This view has been questioned with reference to the discrepancy between active- and passive acts, or implicit promises, and does not generally seem to be supported among practitioners. Our objective was to explore physicians’ and patient organization representatives’ experiences- and perceptions of withdrawing and withholding treatments in a reimbursement priority setting.

Methods Fourteen semi-structured interviews were conducted with Swedish physicians and patient organization representatives from areas with high influx of new treatments, such as oncology, hematology, and neurological diseases, and were analyzed using a thematic analysis.

Results We identified eight different themes which demonstrate relevant factors when withdrawing/withholding treatment: patients’ need of treatment, treatment effect in relation to alternative treatments, patient-professional communication, patient-professional relationship, healthcare responsibility, ethical values, professional support, and reimbursement system.

Discussion We find that practitioners perceive it to be a clinically and ethically significant difference between withdrawing and withholding treatments. We expand on the previous research as we find important ethical values among practitioners, such as perceiving it to be more important to make individual assessments for patients with previous access to treatments than to withdraw it to uphold patient equality. We also identify potential strategies to handle this situation practically. Such strategies could be to: have agreements between the physician and patient about potential future treatment withdrawals, evaluate the treatment’s effect, and to provide guidelines on a national level.